Nosrati Mehdi, Kashani-Sabet Mohammed
Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Methods Mol Biol. 2014;1102:259-73. doi: 10.1007/978-1-62703-727-3_14.
Recent studies in our laboratory have identified novel molecular diagnostic and prognostic markers based on analyses in large cohorts of melanoma patients. These markers were initially derived from gene expression profiling analyses of distinct stages of melanoma progression. Immunohistochemical analyses confirmed the differential expression of these markers, and immunohistochemistry-based multimarker assays were developed to assess melanoma diagnosis and prognosis at the molecular level. In this chapter we review the development of these assays and the methodologies used to assess marker expression in both nevi and primary melanomas.
我们实验室最近的研究基于对大量黑色素瘤患者队列的分析，确定了新的分子诊断和预后标志物。这些标志物最初源自黑色素瘤进展不同阶段的基因表达谱分析。免疫组织化学分析证实了这些标志物的差异表达，并开发了基于免疫组织化学的多标志物检测方法，以在分子水平评估黑色素瘤的诊断和预后。在本章中，我们回顾了这些检测方法的发展以及用于评估痣和原发性黑色素瘤中标志物表达的方法。
